Lilly Ventures
Lilly Ventures is an Indiana-based venture capital firm that provides investment to companies in the life sciences sector.
Business Model:
Revenue: $43.1M
Employees: 51-200
Rankings
Detailed Lilly Ventures Information
Geographic Data
Address: 115 W Washington St
City: Indianapolis
State: IN
Zip: 46204
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Linkedin
Crunchbase
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
Lilly Ventures is the venture capital arm of Eli Lilly and Company responsible for life science investing in North America and Europe. Its primary goal is to facilitate the success of companies in its areas of focus through early to expansion stage investments and value-adding resources. Lilly Ventures currently has $200 million under management and focuses on three major areas of interest. It partner actively with the management teams of its portfolio companies to realize the potential of their technologies.
Contact Phone:
+13174290140
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 3/2015 | Aeglea BioTherapeutics | Series B | 44M |
| 10/2021 | IpiNovyx Bio | Seed Round | 0 |
| 1/2017 | Cavion | Series A | 0 |
| 6/2020 | Evox Therapeutics | Convertible Note | 10M |
| 6/2007 | Serenex | Series D | 0 |
| 11/2010 | Sutro Biopharma | Series C | 36.5M |
| 9/2002 | Serenex | Series B | 15M |
| 10/2005 | Serenex | Series C | 30M |
| 5/2005 | Bayhill Therapeutics | Series B | 35.4M |
| 11/2010 | Cerulean Pharma | Series C | 24M |
| 5/2014 | Lysosomal Therapeutics | Seed Round | 4.8M |
| 6/2014 | Numerate | Series C | 8.2M |
| 1/2015 | Symic Biomedical | Series A | 15M |
| 1/2015 | Surface Oncology | Series A | 35M |
| 2/2015 | Lysosomal Therapeutics | Series A | 20M |
| 3/2008 | Hydra Biosciences | Series C | 34M |
| 9/2003 | Conforma Therapeutics | Series C | 30M |
| 1/2012 | Coherus Biosciences | Series B | 0 |
| 6/2009 | Aileron Therapeutics | Series D | 40M |
| 6/2003 | Nanostream Inc. | Series C | 22M |
| 11/2009 | Trinity Biosystems | Debt Financing | 7.5M |
| 1/2009 | Intradigm Corporation | Series B | 0 |
| 10/2014 | Aileron Therapeutics | Series E | 33M |
| 12/2009 | FORMA Therapeutics | Series B | 3M |
| 6/2018 | Nimbus Therapeutics | Series B | 65M |
| 5/2009 | Avid Radiopharmaceuticals | Series D | 0 |
| 1/2004 | CGI Pharmaceuticals | Series C | 22.3M |
| 3/2013 | Receptos | Series B | 30M |
| 1/2005 | Remon Medical Technologies | Series C | 0 |
| 1/2009 | Hydra Biosciences | Series D | 22M |
| 7/2015 | Protagonist Therapeutics | Series C | 0 |
| 4/2006 | Bayhill Therapeutics | Venture Round | 15.8M |
| 4/2006 | MedManage Systems | Series D | 10.8M |
| 1/2004 | Hydra Biosciences | Series B | 0 |
| 8/2006 | Cabrellis Pharmaceuticals | Series A | 27.5M |
| 12/2012 | Cerulean Pharma | Private Equity Round | 13M |
| 8/2007 | MedManage Systems | Series E | 5M |
| 3/2015 | Nimbus Therapeutics | Series B | 43M |
| 9/2006 | Protagonist Therapeutics | Series A | 9M |
| 1/2007 | Standard BioTools | Series E | 0 |
| 12/2015 | Symic Biomedical | Series A | 0 |
| 9/2012 | FORMA Therapeutics | Series C | 10M |
| 12/2011 | Cerulean Pharma | Series D | 15M |
| 4/2004 | MedManage Systems | Series C | 6M |
| 1/2006 | Avid Radiopharmaceuticals | Series A | 0 |
| 12/2009 | FORMA Therapeutics | Series B | 25.5M |
| 1/2013 | Aileron Therapeutics | Series D | 12M |
| 1/2007 | Cylene Pharmaceuticals | Series C | 44M |
| 9/2010 | Cylene Pharmaceuticals | Series D | 12M |
| 5/2014 | Coherus Biosciences | Series C | 54.7M |
| 11/2013 | Aileron Therapeutics | Series E | 30M |
| 11/2002 | NexCura | Series C | 4M |
| 10/2017 | Kymera Therapeutics | Series A | 30M |
| 7/2009 | Viamet Pharmaceuticals | Series B | 25M |
| 10/2014 | Viamet Pharma | Series D | 60M |
| 9/2004 | Remon Medical Technologies | Series C | 16M |
| 11/2009 | Receptos | Series A | 25M |
| 6/2011 | Nimbus Therapeutics | Series A | 24M |
| 6/2013 | Protagonist Therapeutics | Series B | 0 |
| 11/2007 | Viracta Therapeutics | Series A | 20M |
| 5/2007 | Avid Radiopharmaceuticals | Series C | 0 |
| 2/2006 | InnoCentive | Series A | 9M |
| 4/2010 | Viracta Therapeutics | Series B | 12M |
| 12/2005 | GlobeImmune | Series B | 34.3M |
| 5/2012 | Sutro Biopharma | Series C | 16.5M |
| 7/2018 | Sutro Biopharma | Series E | 0 |
| 3/2012 | Viracta Therapeutics | Series B | 0 |
| 11/2018 | Kymera Therapeutics | Series B | 65M |
| 2/2014 | Aeglea BioTherapeutics | Series A | 0 |
| 3/2012 | Receptos | Venture Round | 30M |
| 10/2021 | IpiNovyx Bio | Seed Round | 0 |
| 6/2020 | Evox Therapeutics | Convertible Note | 0 |
| 11/2018 | Kymera Therapeutics | Series B | 0 |
| 7/2018 | Sutro Biopharma | Series E | 0 |
| 6/2018 | Nimbus Therapeutics | Series C | 0 |
| 10/2017 | Kymera Therapeutics | Series A | 0 |
| 1/2017 | Cavion | Series A | 0 |
| 12/2015 | Symic Biomedical | Series A | 0 |
| 7/2015 | Protagonist Therapeutics | Series C | 0 |
| 3/2015 | Aeglea BioTherapeutics | Series B | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
